Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMpac Group Plc Regulatory News (MPAC)

Share Price Information for Mpac Group Plc (MPAC)

Share Price is delayed by 15 minutes
Get Live Data
262.50    -10.00 (-3.67%)
Bid:
260.00
Ask:
265.00
Spread: 5.00 (1.923%)
Market Cap: £78.94m
MPAC Live PriceLast checked at - London Stock Exchange

Intraday Mpac Group Plc Share Chart

Trading Update

1 Jul 2025 07:00

RNS Number : 0865P
Mpac Group PLC
01 July 2025
 

1 July 2025

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR. 

 

 

Mpac Group plc

(''Mpac'' or the "Group")

 

Trading update, consolidation of US footprint, and notice of results

 

Q2 order intake impacted by tariff uncertainty causing deferral of order decisions which will impact H2 revenue

 

Slower market conditions allow opportunity to accelerate US consolidation plans and optimise cost base for when conditions improve

 

Mpac Group plc, a global leader in high-speed packaging and automation solutions, issues a trading update ahead of the release of its unaudited results for the six months ended 30 June 2025.

 

Revenue in the first half was in line with the Board's expectations, despite the growing macro-economic headwinds resulting from US tariffs. A strong January order book, good performance from the businesses acquired in the prior year, and healthy short-cycle service business all contributed to an H1 operating performance in line with management expectations.

 

However, Original Equipment ("OE") order intake in the core Mpac business (excluding the 2024 acquisitions) has slowed materially through Q2, as customers responded to growing uncertainty around tariffs and low consumer confidence by deferring capital investments and cutting back on spending. The closing order book at 30 June is expected to be circa £90.0m (Dec 2024: £118.5m), providing materially lower than anticipated cover for H2 revenue, with the Americas region particularly impacted. Our services business has remained broadly unaffected, and both of the 2024 acquisitions (BCA and CSi) continue to trade well and in line with management expectations, with CSi specifically benefiting from limited exposure to the US.

 

Q2 order intake is an important period for the Group as orders secured in the period drive H2 revenue flow to where there is typically a natural full year weighting. Accordingly, due to the expected impact from slower orders in Q2 the Board now expects FY 2025 revenue to fall significantly below the Board's previous expectations.

 

Given the current slower market conditions in the US, the Board has decided to take the opportunity to accelerate its plans to consolidate its operational footprint in the US, optimising capacity and the cost base. The Group's facility in Cleveland Ohio will be closed, consolidating it with the business acquired in 2024 in Boston Massachusetts improving utilisation rates. The Group is also reducing capacity in Mississauga Canada. No impact on customers is anticipated. The restructuring will incur non-cash impairment charges in the region of £11.5m.

 

This and other cost saving measures have been designed to maintain existing operating margins despite the reduction in revenue, offsetting the impact of reduced operational leverage. This will further provide a more efficient baseline cost for future growth when global markets improve.

 

The shortfall in customer deposits arising from reduced OE orders also has the effect of marginally increasing June 2025 net debt compared to closing net debt from Dec 2024. Actions to reduce debt have been taken, which include implementing new controls to improve operational efficiency and cash milestone delivery, re-negotiate customer and supplier terms, reduce capital expenditure and minimise discretionary spend. The Group expects to remain comfortably within its covenants.

 

Positively, the Group is also announcing today a 'buy in' transaction for its UK defined benefit pensions scheme and further detail will be set out in a separate announcement. This will help simplify the Group's balance sheet and eliminate a significant risk to Mpac's future profitability and cash flow.

 

The Group expects to announce its unaudited results for the six months ended 30 June 2025 on 23 September 2025.

 

Adam Holland, Chief Executive Officer, commented:

 

"During the later part of the first half of 2025 we have seen the impact of US trade tariffs, falling consumer confidence, and growing economic uncertainty. Customers have increasingly chosen to defer capital investment decisions, with the Americas region being at the epicentre with other regions less impacted to date. Despite resilient first half revenues, the slow down in order intake through H1 2025 means that we must take prompt action now, in anticipation of lower full year revenues and profit than previously expected.

 

Today we announce the restructuring of our US operations, combining two operational sites into a single, more efficient operation in Boston Massachusetts, and reducing capacity in Mississauga Canada.

 

The slowdown of orders and customer deposits has also impacted cash, and net debt rose during the first half of the year. Appropriate control measures have has been implemented to slow and reverse this movement.

 

The actions we take today to simplify our business in response to challenging conditions sets a direction of travel that will position the Group for future growth when markets recover."

 

  

For further information, please contact:

Mpac Group plc

Adam Holland, Chief Executive Officer

Will Wilkins, Chief Financial Officer

Tel: +44(0)24 7642 1100

Shore Capital (Nominated Adviser & Broker)

Advisory

Patrick Castle/Sophie Collins

Broking

Henry Willcocks

 

 

Tel: +44(0)20 7408 4050

 

Panmure Liberum (Joint Broker)

Edward Mansfield

Will King

Freddie Wooding

 

Hudson Sandler

Nick Lyon

Nick Moore

Tel: +44 (0) 20 3100 2000

 

 

 

 

Tel: +44 (0) 20 7796 4133

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTWPUUGQUPAPUU
Date   Source Headline
15th Aug 20247:00 amRNSAcquisition of SIGA Vision Ltd
10th Jul 20247:00 amRNSTrading Update and Notice of Results
22nd May 202412:36 pmRNSFirst FREYR Battery Unit Cell Production Trial
15th May 20243:10 pmRNSResult of AGM
15th May 20247:00 amRNSAGM Statement
26th Apr 20247:35 amRNSSiSTEM pilot battery assembly line
17th Apr 20247:00 amRNSLaunch of ESG Report
9th Apr 20241:12 pmRNSGrant of Options
8th Apr 20242:15 pmRNSNotice of AGM
19th Mar 20247:00 amRNSFull Year Results
21st Feb 20247:00 amRNSEquity Development Investor Presentation
16th Feb 20247:00 amRNSNotice of Results
11th Jan 20247:00 amRNSFull Year Trading Update
4th Dec 202311:51 amRNSDirector/PDMR Shareholding
27th Nov 202311:36 amRNSDirector/PDMR Dealing
18th Oct 20232:42 pmRNSHolding(s) in Company
12th Oct 20237:00 amRNSAppointment of Joint Broker
22nd Sep 202311:19 amRNSHolding(s) in Company
7th Sep 20237:00 amRNSHalf Year Results
17th Aug 20237:00 amRNSEquity Development Investor Webinar
11th Jul 20237:00 amRNSTrading Update and Notice of Results
30th May 202310:52 amRNSDirector/PDMR Shareholding
18th May 202311:17 amRNSResult of Annual General Meeting
17th May 20237:00 amRNSAGM Statement
2nd May 20234:37 pmRNSDirector/PDMR Transaction
6th Apr 20235:30 pmRNSAvailability of Annual Report and Notice of AGM
27th Mar 202310:53 amRNSDirector/PDMR Dealing
22nd Mar 20237:01 amRNSCEO succession
22nd Mar 20237:00 amRNSFull Year Results
20th Feb 20237:00 amRNSEquity Development Investor Presentation
17th Feb 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSFull Year Trading Update
24th Oct 20222:20 pmRNSDirectorate Appointment
14th Oct 202210:58 amRNSReplacement - PDMR Dealing & Total Voting Rights
12th Oct 20224:59 pmRNSDirector/PDMR Dealing & Total Voting Rights
15th Sep 202212:50 pmRNSMpac signs FREYR framework agreement
13th Sep 20227:00 amRNSEquity Development Investor Presentation
9th Sep 20222:16 pmRNSDirector/PDMR Transaction
8th Sep 20227:00 amRNSHalf Year Result
11th Jul 20227:00 amRNSTrading Update and Notice of Results
24th Jun 20222:54 pmRNSAppointment of new auditor
10th Jun 20224:10 pmRNSGrant of Options
27th May 20222:56 pmRNSDirectors/PDMRs Dealing
25th May 20224:13 pmRNSHolding(s) in Company
19th May 20223:57 pmRNSEBT Subscription & Total Voting Rights
13th May 20224:25 pmRNSDirectors/PDMRs Dealing - Replacement
12th May 20224:46 pmRNSDirectors/PDMRs Dealing
4th May 20224:16 pmRNSResult of AGM
4th May 20227:00 amRNSAGM Statement
17th Mar 20227:00 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.